Login / Signup

Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high-risk neuroblastoma clinical trial.

Olivia CampagneHuiyun WuJianrong WuArlene NaranjoVinay M DaryaniAmar J GajjarJulie R ParkClinton F Stewart
Published in: Pediatric blood & cancer (2023)
A simple single-sample approach during topotecan therapy could guide dosing for patients, resulting in more patients reaching target attainment.
Keyphrases
  • end stage renal disease
  • clinical trial
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • mesenchymal stem cells
  • study protocol
  • phase ii
  • childhood cancer